Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer

Medical Technologies. Assessment and Choice
doi 10.31556/2219-0678.2018.32.2.067-080
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Fund Gelios

Related search

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer

Effective Pharmacotherapy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy